bioAffinity Clears Nasdaq Hurdle, Securing Continued Trading for BIAF and BIAFW

Key Points

• bioAffinity Technologies regained compliance with Nasdaq’s minimum bid-price and warrants listing requirements.
• Nasdaq cancelled the company’s previously scheduled hearing before the Nasdaq Hearings Panel.
• bioAffinity common shares and warrants will continue trading on the Nasdaq Capital Market as BIAF and BIAFW.
• The company must remain compliant with all Nasdaq rules to maintain its listing.

bioAffinity Technologies (Nasdaq: BIAF; BIAFW) has regained compliance with Nasdaq listing standards, removing an immediate delisting concern for the company’s common stock and warrants.

Nasdaq confirmed the decision in a letter dated September 8, 2026. bioAffinity shares will continue trading on the Nasdaq Capital Market under the BIAF ticker, while the company’s warrants will remain listed under BIAFW.

Nasdaq Confirms bioAffinity Meets $1 Minimum Bid Requirement

bioAffinity regained compliance with Nasdaq Listing Rule 5550(a)(2), which requires companies listed on the Nasdaq Capital Market to maintain a minimum bid price of $1.00 per share.

The company also regained compliance with Nasdaq Listing Rule 5560(a), which sets listing standards for rights and warrants.

Meeting both requirements removes the immediate listing deficiencies previously facing bioAffinity.

Compliance Decision Cancels Nasdaq Panel Hearing

Nasdaq cancelled bioAffinity’s previously scheduled hearing before the Nasdaq Hearings Panel following the compliance determination.

The hearing would have addressed the company’s ability to continue trading on the Nasdaq Capital Market. With Nasdaq confirming that bioAffinity now meets the relevant standards, the hearing is no longer required.

Continued Nasdaq Listing Supports CyPath Lung Strategy

bioAffinity President and Chief Executive Officer Maria Zannes said maintaining the company’s Nasdaq listing allows management to remain focused on expanding access to CyPath® Lung, the company’s noninvasive lung cancer test.

The company also plans to continue developing its broader pipeline of noninvasive healthcare solutions and building long-term shareholder value.

Ongoing Nasdaq Compliance Still Matters

The notice resolves bioAffinity’s current bid-price and warrants-listing issues, but the company must continue to satisfy all Nasdaq listing standards to remain listed.

For investors, the update removes the near-term uncertainty tied to the cancelled hearing. It does not provide new financial results, sales data, clinical results, or projections for CyPath Lung adoption.